•  
  •  
  •  
  •  

2025-10-01 20:56:45

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Hero MotoCorp Ltd dispatches 687,220 units in September 2025
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Veefin has successfully integrated CRIF's Strategy One BRE with our no-code Digital Lending Stack
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Unimech Aerospace and Manufacturing Ltd experiences slowdown in revenue

Keywords Selected:  INE987B01026

Research

  • Natco Pharma - Natco and Teva launch Revlimid in the US - ICICI Securities

Stock Report

  • NATCO Pharma Ltd updates on acquisition of Adcock Ingram
  • NATCO launches Bosentan Tablets for Oral Suspension in the United States with 180-day exclusivity
  • NATCO Pharma Ltd announces conclusion of USFDA inspection at Pharma Division, Kothur
  • USFDA inspection at the API manufacturing plant located in Mekaguda, Hyderabad
  • NATCO Pharma Ltd - Legal Update regarding Risdiplam
  • Mylan and Novo Nordisk reach settlement of US patent ligitation related to Ozempic
  • NATCO Pharma Canada Inc. announces US$ 8 million investment in eGenesis, Inc.
  • Natco Pharma Ltd announces submission of Abbreviated New Drug Application
  • NATCO Pharma Ltd updates on complaint by Fresenius
  • NATCO Pharma Ltd receives warning letter from USFDA for facility in Kothur, Telangana
  • NATCO Pharma Limited invests around US$ 2 million in Cellogen Therapeutics Private Limited
  • Natco Pharma Ltd and Breckenridge dismissed from antitrust lawsuit
  • Operations disrupted at NATCO Pharma's Manali, Chennai factory
  • NATCO Pharma announces successful completion of USFDA inspection
  • Natco Pharma Ltd receives 8 observations from USFDA for Pharma Division at Kothur
  • NATCO Pharma Ltd included as defendant in antitrust lawsuit in the US
  • NATCO files generic Erdafitinib Tablets in USA
  • NATCO receives final approval for Tipiracil Hydrochloride and Trifluridine for the US market
  • Natco Pharma receives EIR from USFDA for Vizag facility
  • NATCO Pharma Limited to form subsidiary in Indonesia
  • NATCO launches additional strengths for the Generic Version of Revlimid® in USA
  • Natco Pharma Ltd board approves buyback
  • NATCO Pharma Ltd board to consider buyback
  • NATCO launches generic Pomalidomide Capsules in Canada

Latest Post

  • Hero MotoCorp Ltd dispatches 687,220 units in September 2025
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Veefin has successfully integrated CRIF's Strategy One BRE with our no-code Digital Lending Stack
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Unimech Aerospace and Manufacturing Ltd experiences slowdown in revenue


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024